18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Regulatory T (T reg) cells have an immunosuppressive function in cancer, but the underlying mechanism of immunosuppression in the tumor microenvironment (TME) is unclear.

          Methods

          We compared the phenotypes of T cell subsets, including T reg cells, obtained from peripheral blood, malignant effusion, and tumors of 103 cancer patients. Our primary focus was on the expression of immune checkpoint (IC)-molecules, such as programmed death (PD)-1, T-cell immunoglobulin and mucin-domain containing (TIM)-3, T cell Ig and ITIM domain (TIGIT), and cytotoxic T lymphocyte antigen (CTLA)-4, on T reg cells in paired lymphocytes from blood, peritumoral tissue, and tumors of 12 patients with lung cancer. To identify the immunosuppressive mechanisms acting on tumor-infiltrating T reg cells, we conducted immunosuppressive functional assays in a mouse model.

          Results

          CD8 +, CD4 + T cells, and T reg cells exhibited a gradual upregulation of IC-molecules the closer they were to the tumor. Interestingly, PD-1 expression was more prominent in T reg cells than in conventional T (T conv) cells. In lung cancer patients , higher levels of IC-molecules were expressed on T reg cells than on T conv cells, and T reg cells were also more enriched in the tumor than in the peri-tumor and blood. In a mouse lung cancer model, IC-molecules were also preferentially upregulated on T reg cells, compared to T conv cells. PD-1 showed the greatest increase on most cell types, especially T reg cells, and this increase occurred gradually over time after the cells entered the TME. PD-1 high-expressing tumor-infiltrating T reg cells displayed potent suppressive activity, which could be partially inhibited with a blocking anti-PD-1 antibody.

          Conclusions

          We demonstrate that the TME confers a suppressive function on T reg cells by upregulating IC-molecule expression. Targeting IC-molecules, including PD-1, on T reg cells may be effective for cancer treatment.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          TIGIT predominantly regulates the immune response via regulatory T cells.

          Coinhibitory receptors are critical for the maintenance of immune homeostasis. Upregulation of these receptors on effector T cells terminates T cell responses, while their expression on Tregs promotes their suppressor function. Understanding the function of coinhibitory receptors in effector T cells and Tregs is crucial, as therapies that target coinhibitory receptors are currently at the forefront of treatment strategies for cancer and other chronic diseases. T cell Ig and ITIM domain (TIGIT) is a recently identified coinhibitory receptor that is found on the surface of a variety of lymphoid cells, and its role in immune regulation is just beginning to be elucidated. We examined TIGIT-mediated immune regulation in different murine cancer models and determined that TIGIT marks the most dysfunctional subset of CD8+ T cells in tumor tissue as well as tumor-tissue Tregs with a highly active and suppressive phenotype. We demonstrated that TIGIT signaling in Tregs directs their phenotype and that TIGIT primarily suppresses antitumor immunity via Tregs and not CD8+ T cells. Moreover, TIGIT+ Tregs upregulated expression of the coinhibitory receptor TIM-3 in tumor tissue, and TIM-3 and TIGIT synergized to suppress antitumor immune responses. Our findings provide mechanistic insight into how TIGIT regulates immune responses in chronic disease settings.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Tumor immunotherapy directed at PD-1.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers

              Abnormal expression of activating/inhibitory receptors leads to natural killer (NK) cells dysfunction in tumor. Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumor-infiltrating NK cells from patients with digestive cancers including esophageal, liver, colorectal, gastric and biliary cancer. The increased PD-1 expression on NK cells indicates poorer survival in esophageal and liver cancers. Blocking PD-1/PD-L1 signaling markedly enhances cytokines production and degranulation and suppresses apoptosis of NK cells in vitro. PD-1/PD-L1 exerts inhibitory effect through repressing the activation of PI3K/AKT signaling in NK cells. More importantly, a PD-1 blocking antibody was found to significantly suppress the growth of xenografts in nude mice, and this inhibition of tumor growth was completely abrogated by NK depletion. These findings strongly suggested that PD-1 is an inhibitory regulator of NK cells in digestive cancers. PD-1 blockade might be an efficient strategy in NK cell-based tumor immunotherapy.
                Bookmark

                Author and article information

                Contributors
                82-2-2228-2142 , syparkcs@yuhs.ac
                82-2-2228-8130 , rha7655@yuhs.ac
                82-2-2123-2696 , sjha@yonsei.ac.kr
                Journal
                J Immunother Cancer
                J Immunother Cancer
                Journal for Immunotherapy of Cancer
                BioMed Central (London )
                2051-1426
                4 December 2019
                4 December 2019
                2019
                : 7
                : 339
                Affiliations
                [1 ]ISNI 0000 0004 0470 5454, GRID grid.15444.30, Yonsei Cancer Center, Division of Medical Oncology, , Yonsei University College of Medicine, ; 50 Yonsei-ro, Seodaemun-Gu, Seoul, 120-752 South Korea
                [2 ]ISNI 0000 0004 0470 5454, GRID grid.15444.30, Department of Biochemistry, College of Life Science & Biotechnology, , Yonsei University, ; Seoul, South Korea
                [3 ]ISNI 0000 0004 0470 5454, GRID grid.15444.30, Department of Thoracic and Cardiovascular Surgery, , Yonsei University College of Medicine, ; 50 Yonsei-ro, Seodaemun-Gu, Seoul, 120-752 South Korea
                [4 ]ISNI 0000 0004 0470 5454, GRID grid.15444.30, Department of Pathology, , Yonsei University College of Medicine, ; Seoul, South Korea
                [5 ]ISNI 0000 0004 0470 5454, GRID grid.15444.30, Department of Radiation Oncology, , Yonsei University College of Medicine, ; Seoul, South Korea
                [6 ]ISNI 0000 0001 0840 2678, GRID grid.222754.4, Department of Pharmacy, , Korea University, ; Sejong, South Korea
                Article
                785
                10.1186/s40425-019-0785-8
                6894345
                31801611
                32e48007-581b-48c8-92cc-2a9d57659b0a
                © The Author(s). 2019

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 13 December 2018
                : 22 October 2019
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2019

                tumor microenvironment,regulatory t cells,immune checkpoints,programmed cell death 1 receptor

                Comments

                Comment on this article